Developer docs
API playgroundTry for free, no card

Search company profiles

NervGen Pharma

Full company profile

uuid00032bt

Namestring
NervGen Pharma
Legal namestring
NervGen Pharma Corp.
Websiteurl
nervgen.com
Company typeenum
Public
Founded yearint
2018
Descriptiontext

NervGen Pharma Corp. is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Vancouver, British Columbia, with shares trading on Nasdaq under the ticker NGEN since January 8, 2026 (following voluntary delisting from the TSX Venture Exchange on March 16, 2026). The company is purpose-built around a single therapeutic platform of neuroreparative peptides that target the inhibitory CSPG-PTPσ pathway to enable the central nervous system to repair itself. Its lead asset, NVG-291, is a first-in-class 35 amino acid peptide administered as a daily subcutaneous injection for 12 weeks, licensed exclusively worldwide from Case Western Reserve University based on foundational research by Dr. Jerry Silver. The Phase 1b/2a CONNECT SCI study in cervical motor incomplete spinal cord injury produced statistically significant and durable functional improvements — 100% responder rate (10/10) versus 10% placebo (1/10) on the Global Statistical Test (p=0.0001) — with benefits extending up to 364 days post-treatment in chronic patients up to 10 years post-injury.

NervGen's pipeline extends beyond NVG-291 to include the preclinical next-generation candidate NVG-300, the rodent analog NVG-291-R used in translational research, and indication expansion programs in multiple sclerosis (remyelination), Alzheimer's disease, stroke, traumatic brain injury (DoD/WRAIR-funded), traumatic hearing loss (DoD/59th Medical Wing-funded), and peripheral nerve injury (DoD-funded, up to $1.5M). The FDA has granted Fast Track designation for NVG-291 in SCI, with an EMA Orphan Drug designation, and a successful End-of-Phase 2 meeting in April 2026 aligned the FDA on the Phase 3 RESTORE registrational study design in chronic tetraplegia (~150 subjects across U.S. and Canadian sites, initiating mid-2026).

The company is pre-revenue with no commercial product and no product pricing; Q1 2026 financials showed a $1.7 million net loss and $16.6 million cash position, with the TTM loss at $0.40 per share. Operations are funded by capital markets activity and government grants — cumulative disclosed funding exceeds $100 million, including a US$60 million underwritten public offering in May 2026 (joint bookrunners Leerink Partners and TD Cowen), a US$10 million non-brokered private placement in November 2025 (with PFP Biosciences increasing its stake to 18.8%, alongside SCI Ventures and the Paul and Phyllis Fireman Charitable Foundation), a US$15.2 million private placement in July 2022, and an $8 million bought deal in November 2021. Topline Phase 3 RESTORE data is targeted for the first half of 2028, and H.C. Wainwright maintains a Buy rating with a US$18 price target.

Short descriptiontext

NervGen Pharma is a clinical-stage biopharmaceutical company developing NVG-291, a first-in-class neuroreparative peptide targeting the CSPG-PTPσ pathway to enable nervous system repair, with lead Phase 3 program in chronic spinal cord injury and pipeline expansion into MS, Alzheimer's, TBI, and peripheral nerve injury.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersVancouver, Canada
HQ citystring
Vancouver
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neuroreparative therapeutics, spinal cord injury treatment, clinical-stage biopharmaceuticals, peptide drug development, CSPG-PTPσ pathway drugs
Industry2 codes
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Neuroreparative Biopharmaceuticals
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model1 record
1Pre-revenue clinical-stage company
TypeSubscription Recurring
Description

NervGen is a clinical-stage biopharmaceutical company with no product revenue. The company remains unprofitable with a loss of $0.40 per share over the trailing twelve months. All clinical development is funded by capital markets activity (private placements, public offerings, ATM equity program) and government grants. Future revenue is anticipated to come from commercialization of NVG-291, the first potential pharmacologic treatment for spinal cord injury, subject to FDA approval.

investing.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components2 values
Technology or R&D, Personnel
Pricing details1 tier
1Public equity offering pricing — not product pricing
ModelOther
Notes

Public equity priced at US$2.50 per common share in May 2026 underwritten public offering of 24 million shares with warrants exercisable at US$3.68 per share, generating approximately US$60 million gross proceeds. No product pricing available as NVG-291 is not yet approved for commercial sale.

in.investing.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1NVG-291
Description

Lead therapeutic candidate — a first-in-class subcutaneously administered neuroreparative peptide targeting the CSPG-PTPσ pathway for spinal cord injury and other neurologic conditions.

nervgen.com
+3 more records
Core offering1 text field

NervGen Pharma is a clinical-stage biopharmaceutical company developing NVG-291, a first-in-class 35 amino acid neuroreparative peptide administered by daily subcutaneous injection that targets the inhibitory CSPG-PTPσ pathway to enable the central nervous system to repair itself. Its lead program addresses chronic and subacute cervical motor incomplete spinal cord injury (SCI), with FDA Fast Track and EMA Orphan Drug designations; a planned Phase 3 RESTORE registrational study in chronic tetraplegia is targeted for mid-2026 across U.S. and Canadian sites. Pipeline expansion targets multiple sclerosis, Alzheimer's disease, traumatic brain injury, traumatic hearing loss, and peripheral nerve injury.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

NervGen Pharma is a clinical-stage biopharmaceutical company built around a single therapeutic platform of neuroreparative peptides that target the inhibitory CSPG-PTPσ pathway to enable the nervous system to repair itself. Its core asset is the lead peptide NVG-291, currently in the Phase 1b/2a CONNECT SCI Study for chronic and subacute spinal cord injury (with Fast Track designation from the FDA and Orphan Drug designation from the EMA) and advancing into the planned Phase 3 RESTORE registrational study. The next-generation candidate NVG-300 is being evaluated in preclinical models, while the rodent analog NVG-291-R is used in translational research across multiple neurological conditions. Preclinical work in traumatic brain injury and traumatic hearing loss is funded and conducted by the U.S. Department of Defense. Together, NVG-291 and NVG-300 form NervGen's portfolio pursuing a pharmacologic approach to transform the treatment paradigm for neurotraumatic and neurologic conditions.

Product and service2 records
1NVG-291
CategoryLead therapeutic candidate (peptide drug)
Description

First-in-class 35 amino acid neuroreparative peptide administered by daily subcutaneous injection for 12 weeks, targeting the inhibitory CSPG-PTPσ pathway to enable the central nervous system to repair itself; lead therapeutic candidate for chronic and subacute cervical motor incomplete spinal cord injury, with FDA Fast Track designation and EMA Orphan Drug designation.

2NVG-300
CategoryNext-generation preclinical peptide candidate
Description

Internally discovered next-generation peptide candidate being evaluated in preclinical models for neurotraumatic and neurologic conditions with significant unmet medical need, extending the NervGen platform beyond NVG-291.

Scale indicator16 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2026-05-21
Description

Acting as joint bookrunning manager for NervGen's May 2026 underwritten public offering of 24 million common shares at $2.50/share plus warrants, generating approximately $60 million gross proceeds. Also covers NervGen as an analyst. Provides underwriting and capital markets advisory services.

Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2026-05-21
Description

Acting as joint bookrunning manager for NervGen's May 2026 underwritten public offering of $60 million. Also covers NervGen as an analyst (Joe Thome, PhD). Provides underwriting and capital markets advisory services.

Strategic tierFlagshipTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2018-01-01
Description

NervGen was founded in 2018 following many conversations between Dr. Harold Punnett and Dr. Jerry Silver. NervGen holds exclusive worldwide rights to the intellectual property from CWRU covering NVG-291, the foundational therapeutic peptide. The technology is based on Dr. Silver's research identifying the inhibitory CSPG-PTPσ pathway and the discovery of NVG-291 in 2015 as a 35 amino acid peptide.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Clinical trial site partner supporting the Phase 1b/2a CONNECT SCI Study. The company acknowledged the support and participation of the SCI community and the Shirley Ryan AbilityLab in the CONNECT SCI Study. Provides clinical research infrastructure for NVG-291 evaluation in chronic SCI patients.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Preclinical development for traumatic brain injury (TBI) funded and conducted by the U.S. Department of Defense via the Walter Reed Army Institute of Research (WRAIR). October 2022: NervGen received up to $1.5 million in DoD funding to evaluate NVG-291-R for peripheral nerve injury treatment, aimed at establishing preclinical proof-of-concept for nerve regeneration and recovery in military and civilian populations.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Preclinical development for traumatic hearing loss funded and conducted by the U.S. Department of Defense via the 59th Medical Wing. Partnership extends NVG-291-R research into additional neurotraumatic indications relevant to military populations.

Strategic tierCoreTypeTechnology or Integration
Description

AI-powered movement intelligence company specializing in video-based motion capture and computational analysis of standardized walking assessments. Newton Tech conducted the independent, blinded biomechanical gait analyses for the Phase 1b/2a CONNECT SCI study, producing quantitative measures of gait quality (coordination, mechanical effort, postural stability). Statistical methodology and computational analyses independently verified by the Department of Computational Biomedicine at a leading academic medical center.

Strategic tierCoreTypeGTM or Marketing Partner
Description

Media relations firm handling media inquiries for NervGen. Contacts David Schull or Ignacio Guerrero-Ros, PhD at (858) 717-2310. Provides public relations and earned media support.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing Cethrin (BA-2109), a rho inhibitor delivered locally for spinal cord injury repair. Most direct competitor to NervGen's NVG-291 in SCI with overlapping mechanism (targeting inhibitory environment) and similar clinical-stage positioning.

TypeDirect peer
Description

Commercial CNS company with Fampridine (Ampyra) approved for MS walking impairment. Direct peer in neurorehabilitation with SCI/MS patient overlap and commercial-stage CNS infrastructure NervGen lacks.

TypeBroad incumbent
Description

Late-stage biotech developing apitegromab for spinal muscular atrophy and other neuromuscular conditions. Comparable clinical-stage CNS/neuro company with Phase 3 readout dynamics and muscle function/recovery end-points similar to NVG-291's SCI program.

TypeBroad incumbent
Description

Commercial CNS company with Auvelity (dextromethorphan/bupropion) for major depressive disorder. Comparable mid-cap CNS company with similar sales force buildout challenges in specialty neurology and FDA Fast Track use precedent.

TypeBroad incumbent
Description

Clinical-stage antisense oligonucleotide company for genetic CNS disorders including Dravet syndrome. NervGen's Chief Regulatory Officer Shamim Ruff joined from Stoke; comparable clinical-stage CNS biotech with similar FDA regulatory pathway work.

TypeDirect peer
Description

Was a CNS-focused biotech with Skyclarys approved for Friedreich's ataxia (a rare neurological disease with CNS repair mechanism). Acquired by Biogen for $7.3B in 2023 — provides M&A precedent for CNS-focused rare disease biotech with first/best-in-class mechanism and Fast Track designation. Comparable trajectory NervGen could follow.

TypeEmerging player
Description

Japan-based clinical-stage biotech developing hepatocyte growth factor (HGF) for spinal cord injury and ALS. Direct SCI indication overlap with NVG-291 and similar neuro-regenerative therapeutic approach; regional competitor with parallel SCI clinical program.

TypeRegional player
Description

Commercial-stage medical device company with Portable Neuromodulation Stimulator (PoNS) approved for MS gait deficit. Adjacent therapeutic area (neuroplasticity/recovery) with similar SCI/MS patient focus and specialty neurology channel; device rather than pharmacologic modality.

9ArmaGen
TypeEmerging player
Description

Clinical-stage biotech developing IgG fusion proteins that cross the blood-brain barrier to treat CNS disorders. Comparable CNS drug delivery and rare neurological disease focus; partnership/Bayer deal provides comparable BD precedent for CNS biotech.

TypeEmerging player
Description

Clinical-stage gene therapy company for rare CNS disorders including GM1 gangliosidosis and frontotemporal dementia. Comparable clinical-stage neuroscience biotech with similar capital-intensive development model and platform-based pipeline approach.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NervGen Pharma

Neuroreparative Biopharmaceuticalsnervgen.com

NervGen Pharma is a clinical-stage biopharmaceutical company developing NVG-291, a first-in-class neuroreparative peptide targeting the CSPG-PTPσ pathway to enable nervous system repair, with lead Phase 3 program in chronic spinal cord injury and pipeline expansion into MS, Alzheimer's, TBI, and peripheral nerve injury.

What NervGen Pharma does

NervGen Pharma Corp. is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Vancouver, British Columbia, with shares trading on Nasdaq under the ticker NGEN since January 8, 2026 (following voluntary delisting from the TSX Venture Exchange on March 16, 2026). The company is purpose-built around a single therapeutic platform of neuroreparative peptides that target the inhibitory CSPG-PTPσ pathway to enable the central nervous system to repair itself. Its lead asset, NVG-291, is a first-in-class 35 amino acid peptide administered as a daily subcutaneous injection for 12 weeks, licensed exclusively worldwide from Case Western Reserve University based on foundational research by Dr. Jerry Silver. The Phase 1b/2a CONNECT SCI study in cervical motor incomplete spinal cord injury produced statistically significant and durable functional improvements — 100% responder rate (10/10) versus 10% placebo (1/10) on the Global Statistical Test (p=0.0001) — with benefits extending up to 364 days post-treatment in chronic patients up to 10 years post-injury.

NervGen's pipeline extends beyond NVG-291 to include the preclinical next-generation candidate NVG-300, the rodent analog NVG-291-R used in translational research, and indication expansion programs in multiple sclerosis (remyelination), Alzheimer's disease, stroke, traumatic brain injury (DoD/WRAIR-funded), traumatic hearing loss (DoD/59th Medical Wing-funded), and peripheral nerve injury (DoD-funded, up to $1.5M). The FDA has granted Fast Track designation for NVG-291 in SCI, with an EMA Orphan Drug designation, and a successful End-of-Phase 2 meeting in April 2026 aligned the FDA on the Phase 3 RESTORE registrational study design in chronic tetraplegia (~150 subjects across U.S. and Canadian sites, initiating mid-2026).

The company is pre-revenue with no commercial product and no product pricing; Q1 2026 financials showed a $1.7 million net loss and $16.6 million cash position, with the TTM loss at $0.40 per share. Operations are funded by capital markets activity and government grants — cumulative disclosed funding exceeds $100 million, including a US$60 million underwritten public offering in May 2026 (joint bookrunners Leerink Partners and TD Cowen), a US$10 million non-brokered private placement in November 2025 (with PFP Biosciences increasing its stake to 18.8%, alongside SCI Ventures and the Paul and Phyllis Fireman Charitable Foundation), a US$15.2 million private placement in July 2022, and an $8 million bought deal in November 2021. Topline Phase 3 RESTORE data is targeted for the first half of 2028, and H.C. Wainwright maintains a Buy rating with a US$18 price target.

NervGen Pharma firmographics

Firmographics
Name
NervGen Pharma
Legal name
NervGen Pharma Corp.
Website
https://nervgen.com
Company type
Public
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
NervGen Pharma is a clinical-stage biopharmaceutical company developing NVG-291, a first-in-class neuroreparative peptide targeting the CSPG-PTPσ pathway to enable nervous system repair, with lead Phase 3 program in chronic spinal cord injury and pipeline expansion into MS, Alzheimer's, TBI, and peripheral nerve injury.
Ownership category
akta.pro rank

NervGen Pharma industry classification

Industry
Product category
Neuroreparative Biopharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Neuroreparative therapeutics
  • Spinal cord injury treatment
  • Clinical-stage biopharmaceuticals
  • Peptide drug development
  • CSPG-PTPσ pathway drugs

Where NervGen Pharma is headquartered

Location

Headquarters

HQ city
Vancouver
HQ country
Canada
HQ region
North America

Offices2 records

Markets served

NervGen Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel

Revenue model

  1. Pre-revenue clinical-stage company: NervGen is a clinical-stage biopharmaceutical company with no product revenue. The company remains unprofitable with a loss of $0.40 per share over the trailing twelve months. All clinical development is funded by capital markets activity (private placements, public offerings, ATM equity program) and government grants. Future revenue is anticipated to come from commercialization of NVG-291, the first potential pharmacologic treatment for spinal cord injury, subject to FDA approval.

Pricing tiers

ModelBillingPrice
Other—Public equity offering pricing — not product pricing

Go-to-market motion3 records

Distribution channels2 records

Marketing channels8 records

NervGen Pharma product offering

Product offering

Core offering

NervGen Pharma is a clinical-stage biopharmaceutical company developing NVG-291, a first-in-class 35 amino acid neuroreparative peptide administered by daily subcutaneous injection that targets the inhibitory CSPG-PTPσ pathway to enable the central nervous system to repair itself. Its lead program addresses chronic and subacute cervical motor incomplete spinal cord injury (SCI), with FDA Fast Track and EMA Orphan Drug designations; a planned Phase 3 RESTORE registrational study in chronic tetraplegia is targeted for mid-2026 across U.S. and Canadian sites. Pipeline expansion targets multiple sclerosis, Alzheimer's disease, traumatic brain injury, traumatic hearing loss, and peripheral nerve injury.

Product overview

NervGen Pharma is a clinical-stage biopharmaceutical company built around a single therapeutic platform of neuroreparative peptides that target the inhibitory CSPG-PTPσ pathway to enable the nervous system to repair itself. Its core asset is the lead peptide NVG-291, currently in the Phase 1b/2a CONNECT SCI Study for chronic and subacute spinal cord injury (with Fast Track designation from the FDA and Orphan Drug designation from the EMA) and advancing into the planned Phase 3 RESTORE registrational study. The next-generation candidate NVG-300 is being evaluated in preclinical models, while the rodent analog NVG-291-R is used in translational research across multiple neurological conditions. Preclinical work in traumatic brain injury and traumatic hearing loss is funded and conducted by the U.S. Department of Defense. Together, NVG-291 and NVG-300 form NervGen's portfolio pursuing a pharmacologic approach to transform the treatment paradigm for neurotraumatic and neurologic conditions.

Differentiator

Problem solved

Functional benefit

Brands

  • NVG-291: Lead therapeutic candidate — a first-in-class subcutaneously administered neuroreparative peptide targeting the CSPG-PTPσ pathway for spinal cord injury and other neurologic conditions.
  • NVG-300
  • CONNECT SCI Study
  • RESTORE

Products and services

  • NVG-291 First-in-class 35 amino acid neuroreparative peptide administered by daily subcutaneous injection for 12 weeks, targeting the inhibitory CSPG-PTPσ pathway to enable the central nervous system to repair itself; lead therapeutic candidate for chronic and subacute cervical motor incomplete spinal cord injury, with FDA Fast Track designation and EMA Orphan Drug designation.
  • NVG-300 Internally discovered next-generation peptide candidate being evaluated in preclinical models for neurotraumatic and neurologic conditions with significant unmet medical need, extending the NervGen platform beyond NVG-291.

Companies that use NervGen Pharma

Customer profile

Segments4 records

Ideal customer profiles3 records

NervGen Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

NervGen Pharma partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core, flagship and minor.

  • Leerink PartnerscoreGTM or Marketing Partner · 21 May 2026Acting as joint bookrunning manager for NervGen's May 2026 underwritten public offering of 24 million common shares at $2.50/share plus warrants, generating approximately $60 million gross proceeds. Also covers NervGen as an analyst. Provides underwriting and capital markets advisory services.
  • TD CowencoreGTM or Marketing Partner · 21 May 2026Acting as joint bookrunning manager for NervGen's May 2026 underwritten public offering of $60 million. Also covers NervGen as an analyst (Joe Thome, PhD). Provides underwriting and capital markets advisory services.
  • Case Western Reserve University (CWRU)flagshipOEM/ Whitelabel/ Licensing Partner · 1 January 2018NervGen was founded in 2018 following many conversations between Dr. Harold Punnett and Dr. Jerry Silver. NervGen holds exclusive worldwide rights to the intellectual property from CWRU covering NVG-291, the foundational therapeutic peptide. The technology is based on Dr. Silver's research identifying the inhibitory CSPG-PTPσ pathway and the discovery of NVG-291 in 2015 as a 35 amino acid peptide.
  • Shirley Ryan AbilityLabcoreImplementation/ SI/ Consulting PartnerClinical trial site partner supporting the Phase 1b/2a CONNECT SCI Study. The company acknowledged the support and participation of the SCI community and the Shirley Ryan AbilityLab in the CONNECT SCI Study. Provides clinical research infrastructure for NVG-291 evaluation in chronic SCI patients.
  • U.S. Department of Defense (Walter Reed Army Institute of Research / WRAIR)coreStrategic or Co-development PartnerPreclinical development for traumatic brain injury (TBI) funded and conducted by the U.S. Department of Defense via the Walter Reed Army Institute of Research (WRAIR). October 2022: NervGen received up to $1.5 million in DoD funding to evaluate NVG-291-R for peripheral nerve injury treatment, aimed at establishing preclinical proof-of-concept for nerve regeneration and recovery in military and civilian populations.
  • U.S. Department of Defense (59th Medical Wing)minorStrategic or Co-development PartnerPreclinical development for traumatic hearing loss funded and conducted by the U.S. Department of Defense via the 59th Medical Wing. Partnership extends NVG-291-R research into additional neurotraumatic indications relevant to military populations.
  • Newton TechcoreTechnology or IntegrationAI-powered movement intelligence company specializing in video-based motion capture and computational analysis of standardized walking assessments. Newton Tech conducted the independent, blinded biomechanical gait analyses for the Phase 1b/2a CONNECT SCI study, producing quantitative measures of gait quality (coordination, mechanical effort, postural stability). Statistical methodology and computational analyses independently verified by the Department of Computational Biomedicine at a leading academic medical center.
  • Russo PartnerscoreGTM or Marketing PartnerMedia relations firm handling media inquiries for NervGen. Contacts David Schull or Ignacio Guerrero-Ros, PhD at (858) 717-2310. Provides public relations and earned media support.

Scale indicators16 records

Recent moves7 records

Expansion highlights6 records

NervGen Pharma competitors and assessment

Company assessment

Direct peers

  • BioAxone BioSciences: Clinical-stage biotech developing Cethrin (BA-2109), a rho inhibitor delivered locally for spinal cord injury repair. Most direct competitor to NervGen's NVG-291 in SCI with overlapping mechanism (targeting inhibitory environment) and similar clinical-stage positioning.
  • Acorda Therapeutics: Commercial CNS company with Fampridine (Ampyra) approved for MS walking impairment. Direct peer in neurorehabilitation with SCI/MS patient overlap and commercial-stage CNS infrastructure NervGen lacks.
  • Reata Pharmaceuticals: Was a CNS-focused biotech with Skyclarys approved for Friedreich's ataxia (a rare neurological disease with CNS repair mechanism). Acquired by Biogen for $7.3B in 2023 — provides M&A precedent for CNS-focused rare disease biotech with first/best-in-class mechanism and Fast Track designation. Comparable trajectory NervGen could follow.

Broad incumbents

  • Scholar Rock: Late-stage biotech developing apitegromab for spinal muscular atrophy and other neuromuscular conditions. Comparable clinical-stage CNS/neuro company with Phase 3 readout dynamics and muscle function/recovery end-points similar to NVG-291's SCI program.
  • Axsome Therapeutics: Commercial CNS company with Auvelity (dextromethorphan/bupropion) for major depressive disorder. Comparable mid-cap CNS company with similar sales force buildout challenges in specialty neurology and FDA Fast Track use precedent.
  • Stoke Therapeutics: Clinical-stage antisense oligonucleotide company for genetic CNS disorders including Dravet syndrome. NervGen's Chief Regulatory Officer Shamim Ruff joined from Stoke; comparable clinical-stage CNS biotech with similar FDA regulatory pathway work.

Emerging players

  • Kringle Pharma: Japan-based clinical-stage biotech developing hepatocyte growth factor (HGF) for spinal cord injury and ALS. Direct SCI indication overlap with NVG-291 and similar neuro-regenerative therapeutic approach; regional competitor with parallel SCI clinical program.
  • ArmaGen: Clinical-stage biotech developing IgG fusion proteins that cross the blood-brain barrier to treat CNS disorders. Comparable CNS drug delivery and rare neurological disease focus; partnership/Bayer deal provides comparable BD precedent for CNS biotech.
  • Passage Bio: Clinical-stage gene therapy company for rare CNS disorders including GM1 gangliosidosis and frontotemporal dementia. Comparable clinical-stage neuroscience biotech with similar capital-intensive development model and platform-based pipeline approach.

Regional players

  • Helius Medical Technologies: Commercial-stage medical device company with Portable Neuromodulation Stimulator (PoNS) approved for MS gait deficit. Adjacent therapeutic area (neuroplasticity/recovery) with similar SCI/MS patient focus and specialty neurology channel; device rather than pharmacologic modality.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

NervGen Pharma social profiles

Digital presence

NervGen Pharma compliance and trust

Trust signal

Compliance4 records

NervGen Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NervGen Pharma leadership team

Management profile

Number of profiles

Profiles8 records

NervGen Pharma funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NervGen Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NervGen Pharma

What does NervGen Pharma do?

NervGen Pharma is a clinical-stage biopharmaceutical company developing NVG-291, a first-in-class 35 amino acid neuroreparative peptide administered by daily subcutaneous injection that targets the inhibitory CSPG-PTPσ pathway to enable the central nervous system to repair itself. Its lead program addresses chronic and subacute cervical motor incomplete spinal cord injury (SCI), with FDA Fast Track and EMA Orphan Drug designations; a planned Phase 3 RESTORE registrational study in chronic tetraplegia is targeted for mid-2026 across U.S. and Canadian sites. Pipeline expansion targets multiple sclerosis, Alzheimer's disease, traumatic brain injury, traumatic hearing loss, and peripheral nerve injury.

Is NervGen Pharma a public or private company?

NervGen Pharma is a public company. It is classified as public and is currently operating.

When was NervGen Pharma founded?

NervGen Pharma was founded in 2018. It employs 11 to 50 people.

Where is NervGen Pharma based?

NervGen Pharma is headquartered in Vancouver, Canada, in the North America region.

How does NervGen Pharma make money?

One revenue line is on record: pre-revenue clinical-stage company.

Who are NervGen Pharma's main competitors?

Direct peers on record are BioAxone BioSciences, Acorda Therapeutics and Reata Pharmaceuticals. Broad incumbents are Scholar Rock, Axsome Therapeutics and Stoke Therapeutics. Emerging players are Kringle Pharma, ArmaGen and Passage Bio. Helius Medical Technologies is listed as a regional player.

Does NervGen Pharma have an API?

No public API is recorded for NervGen Pharma.

What industry is NervGen Pharma in?

NervGen Pharma's product category is Neuroreparative Biopharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAIAD, Rare Neurology & Neurodegenerative Disorder Therapies. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Quiver QuantitativeNervGen Appoints Sam Jackson as Chief Medical Officer to Lead Phase 3 RESTORE Study of NVG-291 | NGEN Stock NewsNervGen appointed Sam Jackson as Chief Medical Officer to lead the Phase 3 RESTORE study of NVG-291 for spinal cord injury. The study will enroll about 150 participants in the U.S. and Canada, with NVG-291 having received FDA Breakthrough Therapy designation.YahooNervGen Appoints Neuroscience Drug Development Leader Sam Jackson, MD, MBA, as Chief Medical OfficerNervGen appointed Sam Jackson as Chief Medical Officer, effective immediately. He will lead the Phase 3 RESTORE study of NVG-291 for spinal cord injury, with about 150 participants. The company aims to advance NVG-291 toward regulatory approval and explore additional indications.TradingViewNervGen Appoints Neuroscience Drug Development Leader Sam Jackson, MD, MBA, as Chief Medical OfficerNervGen appointed Sam Jackson, MD, MBA, as Chief Medical Officer, effective immediately. He will lead the Phase 3 RESTORE study of NVG-291 for spinal cord injury, with about 150 participants. The company aims to advance NVG-291 toward regulatory approval and explore additional indications.TradingViewNervGen (NGEN) Appoints Sam Jackson as Chief Medical OfficerNervGen appointed Sam Jackson as Chief Medical Officer to lead clinical development strategy and the Phase 3 RESTORE study of NVG-291. The study expects about 150 participants across the US and Canada, with no new trial results disclosed.FinancialContent Business PageNervGen Appoints Neuroscience Drug Development Leader Sam Jackson, MD, MBA, as Chief Medical OfficerNervGen appointed Sam Jackson, MD, MBA, as Chief Medical Officer, effective immediately. He will lead the Phase 3 RESTORE study of NVG-291 for spinal cord injury, with about 150 participants. The company aims to advance NVG-291 toward regulatory approval and expand indications.Stock TitanNervGen appoints Sam Jackson as chief medical officerNervGen appointed Sam Jackson as Chief Medical Officer, bringing expertise in neuroscience trial design and FDA approvals. He will lead the Phase 3 RESTORE study of NVG-291 for spinal cord injury, with about 150 participants. The company aims to advance NVG-291 toward regulatory approval and expand indications.GlobeNewswireNervGen Appoints Neuroscience Drug Development Leader Sam Jackson, MD, MBA, as Chief Medical OfficerNervGen appointed Sam Jackson, MD, MBA, as Chief Medical Officer, effective immediately. He will lead the Phase 3 RESTORE study of NVG-291 for spinal cord injury, with about 150 participants. The company aims to advance NVG-291 toward regulatory approval and potential expansion into additional indications.FinancialContent Business PageNervGen Reports Third Quarter 2026 Financial Results and Provides Business UpdatesNervGen reported Q3 2026 results with a net loss of C$6.4 million and cash of C$80.1 million as of September 30, 2026. The company expects to fund operations through the RESTORE study topline readout in H1 2028. It also plans to request a Type B meeting with the FDA to discuss NVG-291's development.Stock TitanNervGen Q3 results: C$80.1M cash, expected runway to 1H 2028NervGen reported Q3 2026 results with C$80.1M in cash and a net loss of C$6.4M. The company expects its cash to fund operations through the RESTORE study topline readout in 1H 2028. Enrollment in RESTORE is ongoing, with completion expected in H2 2027.Quiver QuantitativeNervGen Receives FDA Breakthrough Therapy Designation for NVG-291 in Chronic Spinal Cord Injury | NGEN Stock NewsNervGen received FDA Breakthrough Therapy designation for NVG-291, a neuroreparative peptide for chronic traumatic cervical motor-incomplete spinal cord injury. The designation follows positive safety and efficacy data from the Phase 1b/2a CONNECT SCI study, and the Phase 3 RESTORE study is enrolling about 150 participants in the U.S. and Canada.